Cargando…

Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation

B-cell depleting anti-CD20 monoclonal antibody therapies are being increasingly used as long-term maintenance therapy for neuroinflammatory disease compared to many non-neurological diseases where they are used as remission-inducing agents. While hypogammaglobulinaemia is known to occur in over half...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tallantyre, E. C., Whittam, D. H., Jolles, S., Paling, D., Constantinesecu, C., Robertson, N. P., Jacob, A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2018
Materias:	Original Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5937879/ https://www.ncbi.nlm.nih.gov/pubmed/29511864 http://dx.doi.org/10.1007/s00415-018-8812-0

Ejemplares similares

Correction to: Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation
por: Tallantyre, E. C., et al.
Publicado: (2018)

The Expanding Field of Secondary Antibody Deficiency: Causes, Diagnosis, and Management
por: Patel, Smita Y., et al.
Publicado: (2019)

Clozapine is associated with secondary antibody deficiency
por: Ponsford, Mark, et al.
Publicado: (2019)

A20 deficiency causes spontaneous neuroinflammation in mice
por: Guedes, Renata Padilha, et al.
Publicado: (2014)

The Development of Ofatumumab, a Fully Human Anti-CD20 Monoclonal Antibody for Practical Use in Relapsing Multiple Sclerosis Treatment
por: Hauser, Stephen L., et al.
Publicado: (2023)

Surface Levels of CD20 Determine Anti-CD20 Antibodies Mediated Cell Death In Vitro
por: Singh, Vijay, et al.
Publicado: (2014)

Ofatumumab: a novel monoclonal anti-CD20 antibody
por: Lin, Thomas S
Publicado: (2010)

Anti-CD20 monoclonal antibodies: reviewing a revolution
por: Casan, J. M. L., et al.
Publicado: (2018)

Anti-CD22/CD20 Bispecific Antibody with Enhanced Trogocytosis for Treatment of Lupus
por: Rossi, Edmund A., et al.
Publicado: (2014)

Editorial: The Complexity of Primary Antibody Deficiencies
por: Quinti, Isabella, et al.
Publicado: (2021)

Structural Characterization of the Full-Length Anti-CD20 Antibody Rituximab
por: Belviso, Benny Danilo, et al.
Publicado: (2022)

Impaired Sars-Cov-2 Specific Antibody Responses in Patients Treated with Anti-CD20 Antibodies
por: Sottini, Alessandra, et al.
Publicado: (2020)

Anti‐CD20 monoclonal antibody therapy in postpartum women with neurological conditions
por: Anderson, Annika, et al.
Publicado: (2023)

Treatment with an anti-CD11d integrin antibody reduces neuroinflammation and improves outcome in a rat model of repeated concussion
por: Shultz, Sandy R, et al.
Publicado: (2013)

The Bs20x22 anti-CD20-CD22 bispecific antibody has more lymphomacidal activity than do the parent antibodies alone
por: Tuscano, Joseph M., et al.
Publicado: (2011)

Radioimmunotherapy of B-cell lymphoma with radiolabelled anti-CD20 monoclonal antibodies
por: Dillman, R. O.
Publicado: (2006)

Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment
por: Du, Fanny Huynh, et al.
Publicado: (2017)

Review of an Anti-CD20 Monoclonal Antibody for the Treatment of Autoimmune Diseases of the Skin
por: Ly, Sophia, et al.
Publicado: (2023)

Anti-drug Antibodies Against a Novel Humanized Anti-CD20 Antibody Impair Its Therapeutic Effect on Primary Biliary Cholangitis in Human CD20- and FcγR-Expressing Mice
por: Moritoki, Yuki, et al.
Publicado: (2018)

Phase I study of chimeric anti-CD20 monoclonal antibody in Chinese patients with CD20-positive non-Hodgkin's lymphoma
por: Gui, Lin, et al.
Publicado: (2016)

Development of Novel Anti-Cd20 Monoclonal Antibodies and Modulation in Cd20 Levels on Cell Surface: Looking to Improve Immunotherapy Response
por: Singh, Vijay, et al.
Publicado: (2015)

Case Report: Use of Obinutuzumab as an Alternative Monoclonal Anti-CD20 Antibody in a Patient With Refractory Immune Thrombocytopenia Complicated by Rituximab-Induced Serum Sickness and Anti-Rituximab Antibodies
por: Blase, Jennifer R., et al.
Publicado: (2022)

Monoclonal antibodies targeting CD20
por: Chang, Chien-Hsing, et al.
Publicado: (2013)

Preventing Hepatitis B Reactivation During Anti‐CD20 Antibody Treatment in the Veterans Health Administration
por: Jasmine Bullard, A., et al.
Publicado: (2018)

An open-label safety and efficacy study of an anti-CD20 antibody (rituximab, Rituxan) for anti-B-cell therapy in the treatment of systemic lupus erythematosus
por: Eisenberg, RA, et al.
Publicado: (2004)

Anti-CD20 Disrupts Meningeal B-Cell Aggregates in a Model of Secondary Progressive Multiple Sclerosis
por: Roodselaar, Jay, et al.
Publicado: (2021)

Obinutuzumab: A Novel Anti-CD20 Monoclonal Antibody for Chronic Lymphocytic Leukemia
por: Evans, Sarah S., et al.
Publicado: (2015)

Inhibitors of SRC kinases impair antitumor activity of anti-CD20 monoclonal antibodies
por: Winiarska, Magdalena, et al.
Publicado: (2014)

Resolution of Q Fever–Associated Cryoglobulinemia With Anti-CD20 Monoclonal Antibody Treatment
por: Hawkins, Kellie L., et al.
Publicado: (2017)

Characterization of anti-CD20 monoclonal antibody produced by transgenic silkworms (Bombyx mori)
por: Tada, Minoru, et al.
Publicado: (2015)

A novel glycosylated anti-CD20 monoclonal antibody from transgenic cattle
por: Zhang, Ran, et al.
Publicado: (2018)

Structural and functional comparability study of anti-CD20 monoclonal antibody with reference product
por: Singh, Sanjay Kumar, et al.
Publicado: (2018)

Bivalent binding on cells varies between anti-CD20 antibodies and is dose-dependent
por: Bondza, Sina, et al.
Publicado: (2020)

Generation of a canine anti-canine CD20 antibody for canine lymphoma treatment
por: Mizuno, Takuya, et al.
Publicado: (2020)

New and Old Anti-CD20 Monoclonal Antibodies for Nephrotic Syndrome. Where We Are?
por: Basu, Biswanath, et al.
Publicado: (2022)

Continuous evolution of magnetic resonance imaging in multiple sclerosis
por: Tallantyre, E. C., et al.
Publicado: (2016)

Nerve sheath tumours
por: Robertson, James A., et al.
Publicado: (2018)

A Preclinical Population Pharmacokinetic Model for Anti‐CD20/CD3 T‐Cell‐Dependent Bispecific Antibodies
por: Ferl, Gregory Z., et al.
Publicado: (2018)

Generation of CD20-specific TCRs for TCR gene therapy of CD20(low) B-cell malignancies insusceptible to CD20-targeting antibodies
por: Jahn, Lorenz, et al.
Publicado: (2016)

CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering
por: Oostindie, Simone C., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_nuc0d8cgdf5qg97dncf2kduldn